In 1967, Dr Frans Trijbels accepted a position in the Paediatric Clinical Chemistry Laboratory at the Nijmegen University Hospital St Radboud, in the Netherlands. The laboratory had two major objectives: to promote patient care and to support scienti¢c research. Frans has acquitted himself excellently in these two objectives. Serving patients' interests has always been his ¢rst and foremost aim and a clinical issue always formed the starting point of his scienti¢c work, which then progressed to publication in collaboration with his clinician colleagues. General clinical chemistry was gradually centralized in the Nijmegen University Hospital and brought for Frans the opportunity of concentrating on advanced and specialized clinical chemistry. In 1988, the laboratory for paediatrics and neurology was established. From then onwards, Frans focused his clinical and research work on the ¢eld of hereditary diseases of metabolism.
Frans Trijbels ¢nished his chemical study at the Rheinisch-WestfÌlische Technische Hochschule in Aachen in 1962. He then undertook research in the department of biochemistry of the medical faculty in Nijmegen, which culminated in his thesisÀn enzymatic study of the metabolism of allantoin in various organisms'. Frans went on to train as a clinical chemist. In those days in paediatrics there was a growing interest in inborn errors of metabolism, stimulated by the potential for micro-analysis of body £uids. That challenge was taken up by Trijbels and in 1969 his ¢rst scienti¢c publication in the ¢eld appeared in Acta Paediatrica Scandinavica. 1 His passion for disturbances in the metabolism of amino acids never left him.
His initiatives over the years led the laboratory to develop a highly specialized and successful homocysteine research interest. In his early years in Nijmegen, Frans started working on purine and pyrimidine metabolism. This began with work on the Lesch-Nyhan syndrome and later to oncological research. Diseases a¡ecting cellular organelles played an important role throughout his work. Initially, he divided his attention between peroxisomal and mitochondrial biochemistry, but he later concentrated on Introduction mitochondria. In the 1960s, the research on mitochondrial myopathies started by using an electron microscope in morphological diagnostic studies. Trijbels stood at the cradle of biochemical research on disturbances in cellular energy supply. The initiatives of Frans Trijbels encouraged many disciplines in Nijmegen to join forces and concentrate their research e¡orts on mitochondrial myopathies. The multidisciplinary investigative approach into mitochondriopathies is still a strong feature of the Nijmegen group's research.
The determination of lactate in body £uids often provided the basis for a de¢nite diagnosis, but Frans realized the importance of further, more advanced diagnostic techniques. He devised many original techniques which measured the activity of oxidative phosphorylation in tissues in order to demonstrate the primary defect underlying the mitochondriopathy. He discovered ways to measure the £ux through the citric acid cycle and the respiratory chain and developed techniques to quantify the activity of individual complexes of the respiratory chain. In some cases even individual subunits could be measured.
The introduction of molecular genetics provided new possibilities for mitochondrial research and laboratory diagnosis. His laboratory is recognized as both a national and international reference laboratory for mitochondrial disturbances and forms the cornerstone of the Nijmegen Centre for Mitochondrial Diseases.
In 1988, Trijbels became head of the Laboratory for Paediatrics and Neurology in Nijmegen and in 1991 he was appointed professor with a`clinical biochemistry' teaching commitment. The scienti¢c output of his laboratory is considerable and of high quality, with 40 -80 scienti¢c papers in peer-reviewed international journals annually. His laboratory is one of the largest metabolic laboratories in the world, with 90 co-workers and eight sta¡ members. Prof Trijbels enjoys great esteem and recognition and is frequently invited to present his work at national and international conferences. In addition to his dedication to patient care and research, he is committed to teaching and training and is an ambassador for the chemical diagnosis of hereditary metabolic diseases. Of the numerous professional positions he has held, I will mention those in the Dutch Society of Clinical Chemistry and the ESN (the Dutch equivalent of the Society for the Study of Inborn Errors in Metabolism). Of particular note was his position as European editor of this journal, the Annals of Clinical Biochemistry, over many, many years. In 2002, Trijbels was awarded the prestigious Gorter en de Graa¡ prize, conferred by the Dutch Society for Clinical Chemistry in recognition of his great merits for clinical chemistry in the Netherlands. The sta¡ of his laboratory are now left with the enormous task of continuing the legacy of highquality patient care and scienti¢c research that was achieved under the leadership of Prof Trijbels.
This special issue of the journal is a tribute by his colleagues on the occasion of his retirement. They all thank Prof Trijbels and wish him good health and many remaining inspiring years.
